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Abstract
Background: The Swedish National Quality Registries (NQRs) contain individual-level health care data for specific
patient populations, or patients receiving specific interventions. Approximately 90% of the 105 Swedish NQRs
include any patient-reported outcome measure, with EQ-5D being the most common. As there has been no
general overview of EQ-5D data within the NQRs, this study fills a knowledge gap by reporting how the data are
collected, presented, and used at different levels of the Swedish health care system.
Methods: All 46 NQRs with a license for the use of EQ-5D were included. Information was retrieved from the
registries’ annual reports or from websites, using a template that was subsequently sent to each registry for
completion and confirmation. If considered necessary, the contact was followed-up with an interview, either in-
person or over the telephone. The uses of EQ-5D were categorised as denoting usage for follow-up, decision-
making, or quality improvement in Swedish health care.
Results: In total, 41 of the 46 licensed registries reported collection of EQ-5D data. EQ-5D is most commonly
collected within registries related to the musculoskeletal system, but it has a wide application also in other disease
areas. Thirty-six registries provide EQ-5D results to patients, clinicians, or other decision-makers. Twenty-two of the
registries reported that EQ-5D data are being used for follow-up, decision-making or quality improvement. The
registries most commonly reported use of data for assessing interventions, and in quality indicators to follow-up
the quality of care at a national level.
Conclusion: Collection and use of EQ-5D data vary across the Swedish NQRs, which may partly be accounted for
by the different purposes of the registries. The provided examples of use illustrate how EQ-5D data can inform
decisions at different levels of the health care system. However, there is potential for improving the use of EQ-5D
data.
Keywords: EQ-5D, Patient-reported outcome measures, PROM, Health-related quality of life, Quality registries,
Quality improvement, Routine measurement
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Background
There are 105 National Quality Registries (NQRs) in
Sweden [1]. The registries contain structured health care
data for specific patient populations, or patients receiv-
ing specific interventions. The data are collected and
registered nationally by routine health care practice pro-
viders, for the purpose of monitoring and developing the
quality of Swedish health care [2]. Many of the registries
began as an initiative of one or several local health care
professionals, either at a specific hospital or at a group
of hospitals (the first one was in 1975) [2]. As years went
by, more and more registries were launched, and eventu-
ally, the need for a national support organisation became
evident. Registries now strive for a high affiliation of
clinics, as well as high and complete coverage of eligible
patients.
The Swedish Government has supported the registries
financially since 1990, and the registries are today jointly
financed by the Swedish Government and the 21 health
care regions that have the main responsibility for provid-
ing health care to their inhabitants in the highly decen-
tralised Swedish health care system [2]. In order to
receive financial support, the registries are required to
take part in an annual monitoring process, and the fi-
nancial support has to be approved by an Executive
Committee [1]. Each registry is supported by an inter-
professional team of health care professionals and re-
searchers, with patient representatives also often in-
cluded [2]. However, the registries have different
purposes and needs, which influence their organisation
and structure.
From their commencement, the registries have focused
on clinical measures such as survival, complications, and
other clinical signs of disease progression in the follow-
up of health care [2]. However, it has become more
common to include one or more patient-reported out-
come measures (PROMs). PROMs are standardised self-
reported measures that are typically developed to cap-
ture a person’s perspective on outcomes related to their
health status or health-related quality of life (HRQoL),
such as symptoms, functioning, overall health, or well-
being [3].
Several potential uses of PROMs in clinical practice
have been identified [4–8]. At an individual level,
PROMs may, for example, be used as a screening tool
(e.g. to detect depression or anxiety), to monitor effects
of a patient’s treatment, and/or to get patients more in-
volved in decisions regarding their own care (shared
decision-making) [4, 6]. In addition, results on an aggre-
gated level may be used in decision aids, to provide pa-
tients and health care professionals with information
regarding the impact of different treatment options, to
inform health technology assessments or reimbursement
decisions regarding the effectiveness of health care
interventions, to evaluate the quality of care within a
practice, and/or to enable providers to benchmark their
performance with others [5, 7, 8].
In a previous review, it was reported that almost 90%
of the NQRs have included at least one PROM [9]. The
most commonly collected PROM was EQ-5D. EQ-5D is
a measure of health, and consists of two parts: a ques-
tionnaire with five items (the descriptive system) that
can be summarised in a health profile; and a visual
analogue scale (EQ VAS) that patients may use to rate
their own health on a scale between 0 (worst imaginable
health) and 100 (best imaginable health) [10, 11]. The
five items in the descriptive system each represent a di-
mension of a person’s health status; mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
There are currently two different versions for adults
(EQ-5D-3L and EQ-5D-5L), and a child-friendly version
for children and adolescents (EQ-5D-Y). The difference
between the two versions for adults is mainly the num-
ber of response levels on each question (three or five),
but the questions have also been slightly modified in the
newest version (EQ-5D-5L) [12]. The responses to the
five questions may be converted to an index value that
can be used for calculating quality-adjusted life years
(QALYs), which is the recommended health outcome
measure used in cost-effectiveness analyses of health
care interventions in many countries [13, 14]. The index
values are obtained from existing value sets that are typ-
ically developed for reimbursement purposes in each
specific country. EQ-5D value sets have been derived
and published for many countries worldwide [15].
The implementation and use of PROMs in clinical
practice is associated with several challenges [16–21].
These challenges include: the patients’ willingness to re-
spond to topics addressed in different PROMs; choosing
the most adequate PROM; interpreting results;
skepticism regarding their usefulness and associated
workload; and how the measurements fit into the way
the care is organised, including (IT) infrastructure. More
generally, low interpretability of output data (e.g. by pa-
tients and care givers), as well as survey fatigue, have
been identified as barriers to the use of clinical registry
data in quality improvement, research, and interactions
with patients [22]. Altogether, these findings highlight
the importance of not only focusing on the data collec-
tion when exploring the implementation of PROMs in
routine health care, but also the need to study the actual
use of PROMs, and their implications in terms of im-
provement of patient care and/or health outcomes.
Experiences from some previous large-scale initiatives
for implementing PROMs in routine care settings have
been described in the literature [21, 23]. Nevertheless,
reports of real-world implementation initiatives are still
limited [5, 24, 25]. Studying the collection and use of
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EQ-5D within the Swedish NQRs represents a unique
opportunity to learn from a real-world case of a large-
scale application of a specific PROM in routine health
care. There has so far been no overview available on
how these registries collect and use the EQ-5D data.
This study fills the gap by reporting how EQ-5D data
are collected, presented, and used at different levels of
the Swedish health care system. The results can be use-
ful for clinicians, researchers, and decision-makers at dif-
ferent levels of the health care system in Sweden, and in
other countries, who may learn from the experiences
and progress of the Swedish national quality registries.
Methods
The aim of the study was to increase knowledge on how
EQ-5D data are collected within the Swedish NQRs, and
how the data are made available and are being used in
the Swedish health care system. All 46 registries with a
license to use EQ-5D at the point of data collection were
included. Ten of these NQRs were sub-registries within
the Swedish Neuro Registries.
Information concerning each registry was based on in-
formation available online, as well as on personal com-
munications with representatives from all 46 registries.
The representatives were persons engaged in the man-
agement and/or development of the registry, for example
as registry holder or being involved in the registry’s work
with PROMs and/or PREMs.
Prior to the data collection, a template including ques-
tions regarding the registries’ collection and use of EQ-
5D was developed by the authors (Table S1). The ques-
tions concerned characteristics of the registry in general,
the collection of PROM data, and specifically EQ-5D
data, administration of the PROM instruments, and use
of PROM data for quality improvement and decision-
making. The template was completed with information
from the registries’ annual reports and/or websites, and
sent by e-mail to a representative from each registry for
confirmation and completion. If considered necessary,
the e-mail contact was followed up with additional ques-
tions over e-mail, or in an interview, either in-person or
over the telephone. The information was retrieved be-
tween August 2018 and June 2019.
For each reported use of the data, the representatives
were asked to provide examples of how EQ-5D data
from their registry are being used for that purpose. Sub-
sequently, the resulting comprehensive information was
condensed and tabulated. The contact persons for each
registry were given the opportunity to confirm the infor-
mation regarding how EQ-5D data are collected (Table
S2–S12), presented, and used (Table 2).
The registries were categorised into disease categories
(e.g., cancer, circulatory system), based on a classifica-
tion system developed by the Swedish Association of
Local Authorities and Regions (SALAR) [1] (Table 1).
The registries were also categorised depending on their
purpose. A “diagnosis registry” was defined as a registry
that follows patients based on a diagnosis, and an “inter-
vention registry” as a registry that follows patients based
on them having received a specific intervention. This
categorisation was performed by the authors in dialogue
with colleagues at the Quality Registry Centre (QRC)
Stockholm, based on the collected information regarding
the criteria for including patients in each registry.
The collected information regarding how EQ-5D
data are made available was categorised to describe the
different ways the results are provided to care givers, pa-
tients, and other decision-makers. The developed cat-
egories included feedback on an aggregated level, as well
as on an individual level. Feedback on the aggregated
level was categorised into feedback presented in: annual
reports/websites; research publications; reports adapted
for individual clinics, units, or teams; reports with pa-
tients as the target group; and other reports. Feedback
on the individual level was categorised into: feedback di-
rected to healthcare professionals entering data; and
feedback to patients.
The use of the data was also categorised to describe
how, and to what extent, the EQ-5D data are being used
for follow-up, quality improvement, or decision-making
at the individual level. The categories represent use in
assessment of interventions, health economic studies,
quality indicators, benchmarking, quality improvement,
and in individual patient consultations. The categorisa-
tion was based on usage as defined by the representa-
tives of the registries, but was modified by the authors in
collaboration with the registries, using the information
in the provided examples. For example, to be categorised
as use in a quality indicator, the EQ-5D data from the
registry had to be presented in a format that the registry
or some other stakeholder defined as a quality indicator.
In addition, we also required that the measure fulfilled
some basic criteria in order to be defined as a quality in-
dicator, i.e. that it represented a quantitative summary of
health care data, had a clear direction of what indicates
good or poor quality, and was relevant and important
for improvement [2, 26]. The quality indicators could
be based on outcome measures describing the health
outcome of the patients (e.g. the patient’s responses to
EQ-5D), or on process measures describing measure-
ment and follow-up (e.g. the proportion of patients that
are being followed-up with EQ-5D) [2].
To be defined as use in benchmarking, the usage re-
ported by the registries had to represent a comparison
of performance in terms of EQ-5D results between dif-
ferent health care providers, with the purpose of asses-
sing the performance of each provider, and identifying
needs for improvement [27]. These comparisons should
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Table 1 Swedish National Quality Registries collecting EQ-5D data, 2018
Registry Registry category Registry type
National Prostate Cancer Register (NPCR) of Sweden Cancer Diagnosis
National Quality Registry for Head and Neck Cancer (SweHNCR) Cancer Diagnosis
National Quality Registry for Oesophageal and Stomach Cancer (NREV) Cancer Diagnosis
National Quality Registry for Atrial Fibrillation and Anticoagulation (AuriculA) Circulatory system Diagnosis
National Quality Registry for Congenital Heart Disease (SWEDCON) Circulatory system Diagnosis
National Quality Registry for Enhancement and Development of
Evidence-Based Care in Heart Disease (Swedeheart)
Circulatory system Diagnosis
The Swedish Catheter Ablation Registry Circulatory system Intervention
The Swedish Heart Failure Registry (SwedeHF) Circulatory system Diagnosis
The Swedish National Quality Registry for Ulcer Treatment (RiksSår) Circulatory system Diagnosis
The Swedish Register for Cardiopulmonary Resuscitation (SRCR) Circulatory system Intervention
National Quality Registry for Pituitary Disease Endocrine organs Diagnosis
National Quality Registry for Infectious Diseases Infection Diagnosis
National Quality Registry for Primary Immunodeficiency (PIDcare) Infection Diagnosis
Better management of patients with OsteoArthritis (BOA) Musculoskeletal system Intervention
National Quality Registry for Hip Fracture Patient Care (RIKSHÖFT) Musculoskeletal system Diagnosis
The National Quality Registry for Podiatric Surgery (RiksFot) Musculoskeletal system Intervention
The Swedish Ankle Registry (Swedankle) Musculoskeletal system Intervention
The Swedish amputation and prosthesis register (SwedeAmp) Musculoskeletal system Intervention
The Swedish Elbow Arthroplasty Register and The Swedish Shoulder
Arthroplasty Register
Musculoskeletal system Intervention
The Swedish Fracture Register (SFR) Musculoskeletal system Diagnosis
The Swedish Hip Arthroplasty Register Musculoskeletal system Intervention
The Swedish Knee Arthroplasty Register Musculoskeletal system Intervention
The Swedish Rheumatology Quality Register (SRQ) Musculoskeletal system Diagnosis
The Swedish Spine Register (SWESPINE) Musculoskeletal system Intervention
The National MMC Follow-Up Program and Quality of Care Registry (MMCUP) Nervous system Diagnosis
The National Quality Registry for Rehabilitation Medicine (Webrehab Sweden) Nervous system Intervention
The Swedish Neuro Registries – Hydrocephalus Nervous system Diagnosis
The Swedish Neuro Registries – Motor Neuron Disease Nervous system Diagnosis
The Swedish Neuro Registries – Multiple Sclerosis Nervous system Diagnosis
The Swedish Neuro Registries – Myasthenia Gravis Nervous system Diagnosis
The Swedish Neuro Registries – Narcolepsy Nervous system Diagnosis
The Swedish Neuro Registries – Parkinson’s Disease Nervous system Diagnosis
The Swedish Quality Registry for Pain Rehabilitation (SQRP) Nervous system Intervention
National Quality Registry for Child and Adolescent Habilitation, HabQ
(HabQ CP, HabQ autism, HabQ Parental support)
Paediatrics Intervention
National Quality Registry for Follow-up of Persons with Cerebral Palsy (CPUP) Paediatrics Diagnosis
BipoläR – the Swedish National Quality Register for Bipolar Disorder Psychiatry Diagnosis
National Quality Registry for Dependency (SBR) Psychiatry Intervention
The Swedish National Quality Register for ECT Psychiatry Intervention
SWIBREG – Swedish Inflammatory Bowel Disease Registry Stomach and intestines Diagnosis
National Quality Registry for Haemophilia Other areas (rare diseases) Diagnosis
National Quality Registry for Systemic Psoriasis Treatment (PsoReg) Other areas (skin disease) Diagnosis
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preferably be case-mix adjusted, which means that the
results have been adjusted for differences in the charac-
teristics of the patient populations.
For the use of EQ-5D to be categorised as use in qual-
ity improvement, it was required that the registry repre-
sentatives reported active use of EQ-5D data in efforts
to improve the quality of care.
As it was found too difficult to separate the use of EQ-
5D data for screening, monitoring, in decision aids, and
for shared decision-making, these were combined in one
category of use at an individual level, in patient consulta-
tions. Decision aids were defined as the presentation and
use of individual or aggregated EQ-5D results to support
health care professionals and/or patients in decisions re-
garding the individual patient’s care. Shared decision-
making refers to the use of EQ-5D results in the discus-
sion between a health care professional and a patient,
with the purpose of encouraging patients to express
their preferences regarding different treatment options,
and to make decisions regarding their care, together
with the care giver, based on the best available evidence
[28].
Results
Collection of EQ-5D data
In total, EQ-5D data were collected in 41 of the 46
registries with a license for collection of EQ-5D
(Table 1). EQ-5D data were most commonly collected
in registries targeting conditions related to the mus-
culoskeletal system, followed by those targeting condi-
tions related to the nervous system, circulatory
system, psychiatry, cancer, infections, paediatrics, ob-
stetrics and gynaecology, stomach and intestines,
endocrine organs, skin diseases, and rare diseases (see
Table S2–S12 and Fig. 1). Fifteen of the registries
with collection of EQ-5D data were intervention
registries, and 26 were diagnosis registries (Table 1).
The two registries that first initiated collection of EQ-
5D data started in 1998 (Fig. 2). These registries were
the Swedish Spine Register (SWESPINE), and the Na-
tional Quality Registry for Rehabilitation Medicine
(Webrehab Sweden). Since 2004, when the Swedish
Elbow Arthroplasty Register and The Swedish Shoulder
Arthroplasty Register started collecting EQ-5D data, the
number of registries collecting EQ-5D has gradually in-
creased. The National Quality Registry for Respiratory
Diseases intended to start collecting EQ-5D data for
both adults and children with asthma and chronic ob-
structive lung disease, but had not begun to at the time
of analysis for this study. In addition, four of the ten
sub-registries within the Neuro registries did not collect
EQ-5D data.
Twenty-three registries reported collection of EQ-
5D-3L data, and 16 registries reported collection of
EQ-5D-5L data. Further, one registry reported collec-
tion of EQ-5D-Y data, and one reported collection of
both EQ-5D-3L and EQ-5D-Y data (Fig. 1, Table S2–
S12). Among the registries collecting EQ-5D-5L data,
seven registries had changed from EQ-5D-3L in 2017
(n = 6) or 2018 (n = 1). Five of these were registries
within conditions related to the musculoskeletal sys-
tem. All but four of the registries containing EQ-5D
data have included EQ VAS since the start of EQ-5D
collection. In one additional registry, the collection of
EQ VAS started when changing to EQ-5D-5L in
2017.
The frequency of measurements varies between the
registries. EQ-5D is either measured before and after
Fig. 1 Number of registries collecting EQ-5D data (2018), per registry category
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interventions (n = 14), continuously at specific time
points (n = 12), at baseline and at one or several follow-
ups (n = 5), at one or several follow-ups without baseline
(n = 3), once per patient (n = 3), at specific ages (n = 1),
before injury (retrospectively) and at follow-up (n = 2),
or whenever the patient wants to (n = 1). Among those
measuring before and after intervention (n = 14), most
registries reported having two or more follow-up mea-
surements (n = 11). The registries with continuous mea-
surements at specific time points (n = 12) were all
diagnosis registries in which EQ-5D was measured every
6 months, annually, at each health care visit or health
care contact, or every second or third year.
The most common mode of administration was to use
paper questionnaires only (n = 20), followed by the use
of either paper or web questionnaires (n = 10), web ques-
tionnaires only (n = 6), and either paper, web question-
naires, or interviews (n = 2). The remaining three
registries reported collection of EQ-5D data using inter-
views (n = 1), paper questionnaires or interviews, (n = 1),
or a paper questionnaire followed up with a telephone
interview (n = 1).
The number of measurements ranged from approxi-
mately 60 individuals with EQ-5D measurements in the
National Quality Registry for Atrial Fibrillation and
Anticoagulation (AuriculA) (since year 2018), and in the
Swedish Neuro Registry for Myasthenia Gravis (since
year 2016), to more than 440,000 measurements in the
Swedish Hip Arthroplasty Registry (since year 2008)
(Table S2–S12).
Presentation of EQ-5D data
The registries reported that EQ-5D results are provided
to care givers, patients, and other decision-makers
through several channels. Aggregated EQ-5D results are
most commonly made available through the registries’
annual reports or websites (n = 29) (for examples of
visualizations, see [29–31]). However, it is also relatively
common for the clinics’ own aggregated EQ-5D data to
be presented in reports directed to each clinic or unit,
and/or as feedback to professional teams (n = 20). In
addition, several registries reported that the EQ-5D re-
sults have been included in scientific publications (n =
18).
Some registries reported that data on an individual
patient level are made available to health care profes-
sionals (n = 17), and/or patients (n = 12), and that data
on an aggregated level are made available to patients
(n = 5), and/or in other types of reports (n = 6). Other
types of reports include national online tools for
monitoring health care, public reports to governmen-
tal agencies, master theses, or other publications re-
garding the health status of the patient group. Only
five registries reported that they are not communicat-
ing EQ-5D data through any channel. Of these, four
registries began collecting EQ-5D in 2016 or 2018.
Use of EQ-5D data for follow-up, quality improvement,
and decision-making
Our study shows that the EQ-5D data from the regis-
tries are being used in quality indicators, for assess-
ment and/or economic evaluations of interventions,
for quality improvement, benchmarking, and/or in in-
dividual patient consultations (Table 2). The use of
the data is described in more detail below. Represen-
tatives from 67% (10/15) of the intervention registries
reported use of EQ-5D data (Table 2). The corre-
sponding number for the diagnosis registries was 46%
(12/26). Nevertheless, representatives from several
registries reported that it is unclear if the data are be-
ing used for any purpose, or that it is not being used
at all (n = 19). Four of these registries began collecting
EQ-5D data in 2017 or 2018.
Fig. 2 Number of registries collecting EQ-5D-3L and EQ-5D-5L, per year (1998–2018)
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Use of EQ-5D data in assessment of interventions and
health economic studies
Ten registries reported that the collected EQ-5D data
are being used to assess health care interventions. For
example, EQ-5D data from the National Quality
Registry for Atrial Fibrillation and Anticoagulation
(AuriculA) have been used in a study that aimed to
assess the effectiveness and cost-effectiveness of a risk
score-based treatment of patients with atrial fibrilla-
tion [32]. Furthermore, EQ-5D data from other regis-
tries have been used to assess the outcome of an
osteoarthritis learning programme [33], biological
treatment in psoriasis [34], pain rehabilitation [35],
treatment of fractures [36], hip arthroplasty [37],
shoulder arthroplasty [38], spine surgery [39], knee
arthroplasty [30], foot surgery [40], and total ankle re-
placement [41, 42]. In addition to AuriculA, four
registries (SQRP, Swespine, MMCUP, and NREV) de-
scribed ongoing collaborations with health economists
to investigate the health economic aspects of the dis-
ease, or specific interventions.
Use of EQ-5D data in quality indicators
In total, ten registries reported use of EQ-5D data in qual-
ity indicators (Table 3). The majority of the described
quality indicators are based on the outcome results of EQ-
5D, but there are also three examples utilising the number
of EQ-5D measurements as a process-based quality indi-
cator for assessment of the follow-up process. The quality
indicators (either outcome- or process-based) are pre-
sented in the registries’ reports, at national platforms, or
on online tools, such as “Health care in numbers” (“Vår-
den i siffror”), or the SVEUS platform. “Health care in
numbers” is a national online tool for quality
improvement in Swedish health care. It is administrated
by SALAR and financed by the 21 regions that are respon-
sible for providing health care in Sweden [50]. SVEUS is a
platform for real time follow-up of health care data, and it
is a collaborative initiative between SALAR and the par-
ticipating health care regions [45].
The outcome-based quality indicators are most com-
monly based on the EQ-5D index values, or on results
from EQ VAS. One of the registries has chosen to focus
Table 2 Frequency of registries reporting use of EQ-5D data, per category of registry and category of use


















n n n (% of registries using EQ-5D)
All registries 41 22 10 (45) 5 (23) 10 (45) 7 (32) 6 (27) 7 (32)
Reported use by type of registry
n n n (% of registries using EQ-5D, within type of registry)
Diagnosis 26 12 3 (25) 3 (25) 4 (33) 2 (17) 3 (25) 5 (42)
Intervention 15 10 7 (70) 2 (20) 6 (60) 5 (50) 3 (30) 2 (20)
Reported use by registry category
n n n (% of registries using EQ-5D, within registry category)
Musculoskeletal
system
11 9 7 (78) 1 (11) 4 (44) 4 (44) 2 (22) 2 (22)
Neurological
system
9 4 1 (25) 2 (50) 1 (25) 2 (50) 3 (75) 3 (75)
Circulatory
system
7 3 1 (33) 1 (33) 2 (67) 0 (0) 0 (0) 0 (0)
Cancer 3 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Psychiatry 3 1 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Paediatrics 2 2 0 (0) 0 (0) 1 (50) 0 (0) 1 (50) 1 (50)
Other areas 2 2 1 (50) 0 (0) 1 (50) 1 (50) 0 (0) 1 (50)
Infection 2 0 – – – – – –
Endocrine
organs
1 0 – – – – – –
Stomach and
intestines
1 0 – – – – – –
aNote that each registry can report several categories of use of EQ-5D data
Ernstsson et al. Journal of Patient-Reported Outcomes            (2020) 4:78 Page 7 of 14
on one of the items (pain/discomfort) of the child-
friendly version EQ-5D-Y as a quality indicator.
Use of EQ-5D data in benchmarking
Seven registries reported that their EQ-5D data are used
for benchmarking (Table 4). Health care regions, or con-
tributing units, are most commonly compared in terms
of EQ-5D index values. In two cases, results from EQ
VAS are compared. The comparisons are either pre-
sented on the registries’ web pages, in annual reports, in
reports to the individual units, or through other portals
such as “Health care in numbers” [50] or SVEUS [45].
Adjustments for differences in patient characteristics
(case-mix) were only reported in two cases.
Use of EQ-5D data for quality improvement
Six registries reported that EQ-5D data from their regis-
try have been used for quality improvement (CPUP,
MMCUP, BOA, Riksfot, SQRP, the Neuro registry for
Motor Neuron Disease). However, quality improvement
projects are most commonly initiated locally by the
health care providers and the representatives for the
Table 3 Use of EQ-5D-data in quality indicators
Registry Description of quality indicator
Quality indicators based on outcome measures - published on national platforms
The registry for Better management of patients
with OsteoArthritis (BOA)
EQ-5D is being used in two quality indicators showing the proportion of patients with knee and
hip osteoarthritis who reach the target level for improved HRQoL 1 year after participation in an
osteoarthritis learning programme [43]. An improvement in HRQoL is defined as an absolute
increase of 0.1 on the EQ-5D index. The goal is for 30% of the patients to reach this level 1 year
after participating in the learning programme.
The Swedish Hip Arthroplasty Register (SHPR) EQ-5D is being used in the quality indicator “Patient-reported results of total hip arthroplasty” [44].
Previously, the indicator was based on the relationship between the patients’ expected and
observed EQ-5D-3L index values 1 year after surgery (Observed results/Expected results × 100). The
expected EQ-5D index value was calculated based on the patients’ age, sex, comorbidities, diagno-
sis, and the EQ-5D measurement before surgery. A value over 100 indicated that the observed re-
sult was better than the expected. In 2019, the EQ-5D index value in this indicator was
replaced by EQ VAS. EQ-5D results are also reported to the SVEUS platform.
The Swedish Spine Register (SWESPINE) Absolute and case-mix adjusted EQ-5D index values 1 year after surgery are presented as quality
indicators on the SVEUS platform [45].
Quality indicators based on outcome measures - published by the registries
The National Quality Registry for Child and
Adolescent Habilitation (HabQ)
The item regarding pain and discomfort in EQ-5D-Y is used in a quality indicator for the follow-up
of the habilitation of children with cerebral palsy [46]. The goal is that less than 5 % report severe
pain or discomfort at the follow-up point when the children are 9 years old.
The Swedish Neuro Registries – Multiple
Sclerosis
The EQ-5D index is used as a quality indicator in the quarterly reports that are sent to the contrib-
uting units. The quality indicator represents the proportion of patients in each region with an
index value < 0 (defined as worst imaginable), 0–0.5 (poor health), 0.5 < 1 (well, not full health),
and 1 (full health).
The National Quality Registry for Dependency
(SBR)
The average EQ VAS results are used as a quality indicator in the monthly or quarterly reports to
contributing units.
The Swedish Hip Arthroplasty Register (SHPR) The average increase in EQ VAS score, 1 year after surgery, is used as one out of eight quality
indicators in a value compass [31].
The Swedish Heart Failure Registry (SwedeHF) The average EQ VAS outcome for patients with moderate or pronounced impaired systolic
function will be used as a quality indicator for health status in a new online tool that is about to
be launched. The results of a set of quality indicators are presented for each of the reporting units.
Quality indicators based on process measures
The National Quality Registry for Podiatric
Surgery (RiksFot)
The number of EQ-5D-3L measurements is used in a quality indicator in “Health care in numbers”.
The quality indicator represents the proportion of patients who have reported their health with
EQ-5D and the Self-reported foot and ankle score (SEFAS) before surgery [47].
National Quality Registry for Systemic Psoriasis
Treatment (PsoReg)
The number of EQ-5D-3L measurements (descriptive system) from PsoReg is used by the National
Board of Health and Welfare in two quality indicators representing the proportion of persons with
severe psoriasis who have received a structured assessment of treatment effects with clinical mea-
sures and PROM, each year and 3 to 12 months after initiation of systemic treatment [48]. EQ-5D-
3L is one of three instruments that should be included in the structured assessment.
National Quality Registry for Congenital Heart
Disease (SWEDCON)
The number of EQ-5D-3L measurements are used in a quality indicator aiming to stimulate the
follow-up of the national mission to provide surgery for Grown Up Congenital Heart Disease
(GUCH) at Sahlgrenska University Hospital and Skåne University Hospital [49]. The quality indicator
summarises the proportion of patients who have had a follow-up regarding their quality of life 6–
18months after surgery.
Note: HRQoL health-related quality of life, PROM Patient-reported outcome measure, VAS visual analogue scale
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registries could in most cases not provide detailed infor-
mation regarding these initiatives.
Use of EQ-5D results during individual patient consultations
EQ-5D data from seven registries were reported as being
used for screening and monitoring, as supporting clinical de-
cisions for individual patients, and/or for shared decision-
making during individual patient consultations (Table 5). For
these purposes, the patients’ individual data are most com-
monly used, but there is also one example of aggregated data
being used to inform how other patients have experienced
their HRQoL after surgery (RiksFot).
Discussion
Main findings
This study presents a real-world case where a specific
PROM has been implemented on a large scale in routine
health care. It intends to contribute to the knowledge re-
garding routine collection of PROMs in clinical practice
by describing how EQ-5D is collected, presented, and
used for different purposes. Our findings indicate that
EQ-5D is most commonly collected within registries re-
lated to the musculoskeletal system, and that it has a
wide application among the disease areas covered by the
registries. Data collection has increased continuously,
with growing interest in EQ-5D-5L over the last 7 years.
Most registries provide some feedback regarding the
results of the EQ-5D data collection to patients, clini-
cians, or other decision-makers, most commonly on an
aggregated level. Individual responses are, to some
extent, also made available to treating clinicians and/or
the individual patients, e.g. for shared decision-making.
The collected EQ-5D data are most commonly used for
assessing interventions, and as quality indicators for
following up the quality of care. The provided examples
illustrate how the EQ-5D data can be analysed and sum-
marised to provide information for decisions at different
levels of the Swedish health care system.
Yet, there are areas for improvement to consider. Al-
though EQ-5D outcomes are made available and are be-
ing used, it is, based on our findings, unclear whether
the data influence actual health care decisions, and if
such influence leads to better health outcomes. To im-
prove the quality of care, information from quality indi-
cators and benchmarking needs to be actively used in
quality improvement efforts, which was reported by only
a few of the registries. In addition, representatives from
almost 50% of the registries reported that the EQ-5D
data are not being used, or that they are unaware of
whether the data are being used.
Interpretation of study findings and comparison to
previous research
Limited use of PROMs data has previously been observed
in initiatives for implementing PROMs in clinical practice
[23]. Proposed explanations include a perception that the
collected data are not fit for purpose, and that there are
challenges associated with accessing, understanding and
acting on the results [19]. Several authors have empha-
sised the importance of the collected data being perceived
Table 4 Use of EQ-5D data for benchmarking
Registry Description of benchmarking
The registry for Better management of patients
with OsteoArthritis (BOA)
Quality indicators based on EQ-5D index data from BOA, presented in “Health care in numbers”
(Table 3), are not only presented on a national level, but also per region.
The Swedish Hip Arthroplasty Register (SHPR) The quality indicator based on EQ VAS data from SHPR presented in “Health care in numbers”
(Table 3) are presented per reporting unit, and on a regional and national level. Observed
outcomes are compared with expected outcomes (based on age, sex, diagnosis, Charnley class and
pre-operative PROM results).
Swedish Spine Register (Swespine) Individual clinics connected to the registry may create reports with their own EQ-5D results com-
pared to those of other clinics and the national average. Absolute and case-mix adjusted EQ-5D
index values 1 year after surgery are also presented per unit for those units that are connected to
the SVEUS platform [45].
The Swedish Neuro Registries – Multiple
Sclerosis
The EQ-5D index is presented per region on the registry’s Visualisation and Analysis Platform (VAP),
which can be accessed by health care providers [29]. In the quarterly reports to the units, the re-
sults of the quality indicator for each unit are also presented in comparison with the results of
other units.
The Swedish Quality Registry for Pain
Rehabilitation (SQRP)
The average EQ-5D index and EQ VAS scores, before and after pain rehabilitation, are presented for
all contributing units in the annual report [51]. The number of patients with improvements, no
change, or deteriorations in the EQ-5D index and EQ VAS are also presented per unit. A change in
the EQ-5D index is defined as a difference of more than 0.1 before and after rehabilitation. For EQ
VAS, a change is defined as at least a 20% difference between the measurements.
National Quality Registry for Systemic Psoriasis
Treatment (PsoReg)
The average EQ-5D index is presented per clinic in the annual report [52].
The National Quality Registry for Podiatric
Surgery (RiksFot)
The average EQ-5D index before, and 1 year after, surgery are for all contributing units publicly
available on the registry webpage [40].
Note: PROM Patient-reported outcome measure, VAS visual analogue scale
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as relevant and meaningful by the health care personnel
who invest their time and effort to collecting it [5, 20, 21,
53]. Thus, for a successful implementation in clinical prac-
tice, it has been recommended to have a clear goal when
starting the collection, and to involve relevant stake-
holders in the planning phase [21].
The incentives for including PROMs in the NQRs
have, until recently, largely focused on whether PROM
data are collected. In 2010, the collection of patient-
reported measures became a requirement for the
registries to reach a certain certification level [9]. As the
certification level is linked to the financing of the regis-
try [54], it has likely created an incentive for the regis-
tries to primarily initiate the collection of PROM data,
which has also been mentioned by several of the registry
representatives. Today, data collection from patient-
reported measures is still a criterion in the certification
process, but only if it is considered relevant to the scope
of the registry [54]. More importantly, the revised criter-
ion is focused on whether data from patient-reported
measures are made publicly available.
Since 2014, the registries also need to specify how
PROM data are used for quality improvement in their
annual funding applications submitted to SALAR [9].
However, this is usually a result of local initiatives and,
as supported by our findings, the registries may be un-
aware whether the data are used for quality
improvement or not. Notably, several representatives
from the registries commented that there is no demand,
or only a limited demand, for the EQ-5D data from
health care providers. Whether this is because the health
care providers do not know that the data are available,
or how it can be used, or if they do not find the data
relevant, was difficult to assess in this study.
For the results to be actionable, previous literature em-
phasizes that the data must be analysed and presented in
a way that users can easily interpret and understand [24,
55]. Interestingly, our study has shown that the analysis
of the EQ-5D data from the registries has quite often
been focused on the mean EQ-5D index value, which
summarises the responses to the five questions into one
overall index, based on country-specific value sets. These
value sets are mainly developed for use in health eco-
nomic evaluations, and are most commonly based on
techniques for eliciting preferences for hypothetical
health states among the general public [15]. However,
our study reveals that the use of the EQ-5D data from
the NQRs is considerably focused on the clinical con-
text. For such purposes, alternative analysis methods
have been recommended, that place more focus on the
patients’ responses to the individual items, and their rat-
ing on EQ VAS [56, 57]. Furthermore, local improve-
ment teams may face additional challenges when making
use of PROMs data from the NQRs in local quality
Table 5 Use of EQ-5D results during individual patient consultations (with the purpose of screening, monitoring, decision aids and/
or shared decision-making)
Registry Description of use in decisions at an individual level
The Swedish Neuro Registries – Multiple Sclerosis The registry provides a clinical support tool, that includes EQ-5D and eleven other health mea-
sures, to share the results of each patient with clinicians and the patients themselves. The latest
reported results from EQ-5D and eleven other health parameters are presented in the so called
Function Watch [29]. In this tool, the individual patient’s outcome is compared to those of a ref-
erence group from the registry with comparable characteristics regarding sex, age, MS duration
and treatment status of the patient. The tool is used by neurologists to assess whether the out-
come of a treatment is acceptable, and what problems should be addressed during the individual
patient consultations. The registry has also reported that some neurologists use this information
together with the patients when discussing the patient’s situation, and in making decisions re-
garding treatment.
The Swedish Rheumatology Quality Register (SRQ) The registry provides care givers and patients with a table overview, including EQ-5D results over
time. The overview may be used before and during meetings with the patients for discussion
and decisions regarding treatments.
The National MMC Follow-Up Program and Qual-
ity of Care Registry (MMCUP)
Results from EQ-5D are used in combination with other measures to secure care for the individ-
ual patient, and to support the choice of treatment in the follow-up programme, linked to the
National MMC Follow-Up Program and Quality of Care Registry (MMCUP).
The National Quality Registry for Child and
Adolescent Habilitation (HabQ)
Individual EQ-5D data are used by the health care providers for individual feedback to patients,
and for shared decision-making.
The National Quality Registry for Haemophilia Individual EQ-5D data are used by the treating units for individual feedback to the patients dur-
ing consultations, and can be used to monitor the individual patient’s treatment.
The Swedish Neuro Registries – Motor Neuron
Disease
Individual EQ-5D results are being used in conjunction with data from the Hospital Anxiety and
Depression Scale (HADS) to make decisions about treatment with antidepressants for individual
patients. If the EQ-5D scores are low but the depression scores are satisfying, EQ-5D reveals the
need to identify other reasons for poor HRQoL.
The National Quality Registry for Podiatric Surgery
(RiksFot)
Aggregated EQ-5D data are used to show patients facing surgery how a group of patients who
have undergone the corresponding surgery experience their symptoms 1 year later.
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improvement initiatives, as these may have differing
needs regarding the type of instrument, as well as the
timing and frequency of measurements.
Other possible explanations for the relatively limited
reported use of EQ-5D data from the NQRs are that
some of the registries only recently began collecting
data, that the coverage is too low for the analysis to be
considered meaningful, or that the use of the data is
more focused around other measures collected in the
registry. Hence, attention must be given to that the
NQRs are collecting other health outcome measures,
and that the findings and interpretations from our study
are limited to the use of EQ-5D data only.
Strengths and limitations
The information in this study has been collected in col-
laboration with at least one representative from each of
the included registries, and we have therefore had access
to the most updated information from each registry. All
representatives had the opportunity to confirm or mod-
ify the compiled information regarding the collection,
presentation, and use of EQ-5D data from the registry.
Yet, relying on information from one or two represen-
tatives may also have some limitations. First, the infor-
mation provided may be influenced by whom we were in
contact with. The representatives from the registries
may have interpreted the questions differently. Thus, it
is possible that some information may have been missed,
and our aggregated quantitative analysis should conse-
quently be interpreted with caution. Nevertheless, the
findings on the specific uses of EQ-5D data have been
strengthened by the fact that we have asked for exam-
ples and references.
Second, as previously mentioned, the representatives
from the registries may be unaware of how the data have
been used in clinical practice, or in decision-making by
other stakeholders. This study limitation is especially
prominent in the interpretation of use in quality im-
provement. As quality improvement work is most com-
monly performed locally by the health care providers,
we have not been able to go into depth regarding the
characteristics of these initiatives. We found that collect-
ing this information would have required interviews with
a large number of care givers, which was beyond the
scope of this study. Thus, additional studies are needed
to explore how PROMs are currently integrated in qual-
ity improvement initiatives in health care.
Third, the template that was distributed and discussed
together with the registry representatives included both
open questions and examples (e.g., of channels for feed-
back and use of data). It could be considered a limitation
that examples were provided, as this may have
influenced their responses. However, the personal com-
munications with the registry representatives enabled
good dialogue regarding the questions in the template,
and how these were applicable for each particular
registry.
Finally, we have only been in contact with the regis-
tries that currently have a license for using EQ-5D.
Thus, we do not have any information on why other
registries have decided not to use EQ-5D, or why some
registries that previously collected EQ-5D data have
stopped.
Implications
The initiative to collect EQ-5D within the Swedish
NQRs is one of the most ambitious large-scale PROM
implementations that we have been able to identify in
the literature. Our study is the first to describe this ini-
tiative in detail, and contains several valuable examples
of how PROM data can be collected and used for
follow-up and decision-making. It also shows a potential
for improving the use of EQ-5D, such as setting up clear
goals for data collection, together with the stakeholders,
and considering alternative data analyses in order to im-
prove the interpretability of the results, including a focus
on the specific items of EQ-5D, and case-mix adjust-
ments. In this process, the guidelines developed by ISO-
QOL may provide useful guidance considering aspects
such as the purpose of collecting the data, key barriers
that need to be addressed, and how, when, and where
the results could be presented [18, 21].
Our findings suggest that the case of EQ-5D within
the NQRs provides opportunities to study whether the
use of PROMs leads to actual improvements in patient
care. Although some previous studies indicate that the
use of PROMs is associated with improved communica-
tion and decision-making [58], reviews of the scientific
literature have highlighted that there is limited evidence
for the effects from implementing and using PROMs in
clinical practice [5, 58–60]. Thus, there is a need for fu-
ture studies to investigate if the use of PROMs has an
actual effect on the decisions made by patients and care
givers, and ultimately improves the care and health of
the patients. The examples presented in our study may
provide useful real-world cases for follow-up.
Conclusions
This study contributes to the field of routine collection
of PROMs in clinical practice by describing how EQ-5D
data are collected within the Swedish NQRs, as well as
how results are presented and used at different levels of
the Swedish health care system. It shows that the collec-
tion and use of EQ-5D data vary across the registries,
which may be explained in part by the different purposes
of the registries. Although our study has shown multiple
valuable examples of the usefulness of EQ-5D data as a
PROM, it has also revealed that there is potential for
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improving feedback and the use of the data at different
levels of the health care system.
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